Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

<p>On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria (COVID 19 Vaccine (ChAdOx1 S [recombinant])) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. </p><p>Vaxzevria was granted conditional marketing authorisation in the EU on 29 January 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorization, valid for 5 years, on 31 October 2022. </p><p>The European Public Assessment Report (EPAR) for Vaxzevria is updated to indicate that the marketing authorisation is no longer valid.</p>